Trump Administration Unveils Deal With Regeneron to Lower Drug Prices

President Trump announced a finalized agreement with Regeneron Pharmaceuticals, the last major company to agree to the administration's most-favored-nation pricing plan. This deal marks a significant victory for the administration's efforts to lower drug costs and increase market competition. The move aims to reduce the financial burden on American families while establishing a new standard for pharmaceutical pricing transparency.